BCM
NVO

Brookmont Capital Management’s Novo Nordisk NVO Stock Holding History

Brookmont Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-78,859
Closed -$4.01M – 61
2025
Q4 		$4.01M Buy
78,859
+1
+0% +$51 2.32% 12
2025
Q3 		$4.38M Buy
78,858
+21,725
+38% +$1.27M 2.43% 7
2025
Q2 		$3.94M Sell
57,133
-499
-0.9% -$33.9K 2.26% 11
2025
Q1 		$4M Buy
57,632
+13,323
+30% +$1.1M 2.26% 12
2024
Q4 		$3.81M Buy
44,309
+4,896
+12% +$529K 2.04% 14
2024
Q3 		$4.69M Buy
39,413
+851
+2% +$113K 2.41% 8
2024
Q2 		$5.5M Sell
38,562
-646
-2% -$85.6K 3.01% 4
2024
Q1 		$5.03M Sell
39,208
-14,402
-27% -$1.71M 2.65% 6
2023
Q4 		$5.55M Sell
53,610
-2,368
-4% -$234K 3.11% 3
2023
Q3 		$5.09M Sell
55,978
-458
-0.8% -$40.3K 3.17% 3
2023
Q2 		$4.57M Sell
56,436
-50
-0.1% -$4.08K 2.75% 5
2023
Q1 		$4.49M Sell
56,486
-17,812
-24% -$1.26M 2.83% 4
2022
Q4 		$5.03M Sell
74,298
-2,316
-3% -$136K 3.09% 2
2022
Q3 		$3.82M Buy
76,614
+4,448
+6% +$238K 2.65% 6
2022
Q2 		$4.02M Sell
72,166
-8,950
-11% -$497K 2.77% 5
2022
Q1 		$4.5M Sell
81,116
-20
-0% -$1.03K 2.7% 5
2021
Q4 		$4.54M Sell
81,136
-3,574
-4% -$194K 2.4% 5
2021
Q3 		$4.07M Sell
84,710
-1,992
-2% -$96.3K 2.4% 8
2021
Q2 		$3.63M Sell
86,702
-32
-0% -$1.24K 2.2% 12
2021
Q1 		$2.92M Sell
86,734
-728
-0.8% -$25.9K 1.88% 16
2020
Q4 		$3.06M Sell
87,462
-2,736
-3% -$94.6K 2.15% 12
2020
Q3 		$3.13M Buy
90,198
+1,414
+2% +$47.1K 2.33% 8
2020
Q2 		$2.91M Sell
88,784
-35,852
-29% -$1.14M 2.33% 9
2020
Q1 		$3.75M Sell
124,636
-5,408
-4% -$161K 3.02% 4
2019
Q4 		$3.76M Sell
130,044
-12,858
-9% -$356K 2.25% 12
2019
Q3 		$3.69M Sell
142,902
-42,128
-23% -$1.07M 2.11% 16
2019
Q2 		$4.72M Buy
185,030
+592
+0.3% +$14.6K 2.84% 6
2019
Q1 		$4.82M Buy
184,438
+96
+0.1% +$2.36K 2.97% 4
2018
Q4 		$4.25M Buy
184,342
+19,370
+12% +$430K 2.89% 5
2018
Q3 		$3.89M Sell
164,972
-176
-0.1% -$4.29K 2.32% 12
2018
Q2 		$3.81M Buy
165,148
+3,924
+2% +$93.3K 2.4% 9
2018
Q1 		$3.97M Sell
161,224
-148,622
-48% -$3.9M 2.63% 8
2017
Q4 		$8.31M Buy
309,846
+115,970
+60% +$2.95M 3.58% 7
2017
Q3 		$4.67M Sell
193,876
-4,102
-2% -$92.7K 2.56% 10
2017
Q2 		$4.25M Sell
197,978
-6,548
-3% -$132K 1.6% 23
2017
Q1 		$3.51M Buy
204,526
+23,640
+13% +$412K 1.3% 28
2016
Q4 		$3.24M Sell
180,886
-40,762
-18% -$739K 1.28% 28
2016
Q3 		$4.61M Buy
221,648
+159,066
+254% +$3.94M 1.72% 23
2016
Q2 		$1.68M Sell
62,582
-35,698
-36% -$979K 0.61% 36
2016
Q1 		$2.66M Sell
98,280
-7,378
-7% -$198K 0.85% 34
2015
Q4 		$3.07M Buy
105,658
+4,772
+5% +$132K 0.87% 35
2015
Q3 		$2.74M Sell
100,886
-4,676
-4% -$132K 0.78% 36
2015
Q2 		$2.89M Sell
105,562
-17,028
-14% -$479K 0.73% 37
2015
Q1 		$3.27M Buy
122,590
+82,368
+205% +$1.9M 0.82% 37
2014
Q4 		$851K Buy
+40,222
New +$898K 0.25% 46

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Brookmont Capital Management's NVO Position: Q1 2026 in Review

Brookmont Capital Management sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 78,859 shares — an estimated $4.01M sold.

Brookmont Capital Management first reported a position in NVO in Q4 2014 and held it in 45 quarters. The position peaked at $8.31M in Q4 2017. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Brookmont Capital Management reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Brookmont Capital Management sold 78,859 Novo Nordisk shares in Q1 2026, an estimated $4.01M.
  • Brookmont Capital Management first reported a position in Novo Nordisk in Q4 2014 and held it in 45 quarters.
  • Brookmont Capital Management's Novo Nordisk position peaked at $8.31M in Q4 2017.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Brookmont Capital Management's 13F filing for Q1 2026, filed 15 May 2026.